# IHCP bulletin

INDIANA HEALTH COVERAGE PROGRAMS


BT2023157 NOVEMBER 9, 2023

## IHCP adds coverage for RSV immunization Beyfortus for the pediatric population

On July 17, 2023, the U.S. Food and Drug Administration (FDA) approved use of the respiratory syncytial virus (RSV) immunization, Beyfortus, for use in neonates and infants born during or entering their first RSV season, and in children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season (see FDA news release).

Effective immediately, for dates of service (DOS) on or after **July 17**, **2023**, the Indiana Health Coverage Programs (IHCP) will reimburse IHCP-enrolled providers for the administration of the Beyfortus RSV immunization to members ages from birth to 24 months old. Providers should use the Current Procedural Terminology® codes listed in Table 1 for the immunization, along with administration code 96372 – *Injection of drug or substance under skin or into muscle*. Because this immunization is available through the Vaccines for Children (VFC) program, IHCP reimbursement is limited to the administration fee only.

The claim-processing system has been updated, and claims will be mass adjusted or reprocessed for DOS on or after **July 17, 2023**. Providers should see adjusted or reprocessed claims on remittance



Prior authorization (PA) and National Drug Code (NDC) are not required.

The new codes will be reflected in the next regular update to the Professional Fee Schedule and Outpatient Fee Schedule, accessible from the <u>IHCP Fee Schedules</u> page at in.gov/medicaid/providers.

This billing and reimbursement information applies to services delivered under the fee-for-service (FFS) delivery system. Questions about FFS billing and reimbursement should be directed to Gainwell Technologies at 800-457-4584.

Individual managed care entities (MCEs) establish and publish PA, billing and reimbursement information within the managed care delivery system. Questions about managed care PA, billing or reimbursement should be directed to the MCE with which the member is enrolled.



Table 1 – Newly covered RSV immunization, Beyfortus, effective for DOS on or after July 17, 2023

Procedure code	Description	Program coverage	PA required	NDC required	Reimbursement notes
90380	Respiratory syncytial virus, monoclonal antibody, seasonal dose; 0.5 mL dosage, for intramuscular use	Covered under Traditional Medicaid and other IHCP programs that include full Indiana Medicaid State Plan benefits; the service may not be covered under IHCP plans with limited benefits	No	No	Max Fee: \$0.00
					Restricted to members birth to 24 months old
					Reimburses at \$0 for members up to 24 months of age due to availability through the VFC, effective Aug. 3, 2023. For VFC billing guidance, see BT201960.
90381	Respiratory syncytial virus, monoclonal antibody, seasonal dose; 1 mL dosage, for intramuscular use	Covered under Traditional Medicaid and other IHCP programs that include full Indiana Medicaid State Plan benefits; the service may not be covered under IHCP plans with limited benefits	No	No	Max Fee: \$0.00
					Restricted to member birth to 24 months old
					Reimburses at \$0 for members up to 24 months of age due to availability through the VFC, effective Aug. 3, 2023. For VFC billing guidance, see <u>BT201960</u> .

### QUESTIONS?

If you have questions about this publication, please contact Customer Assistance at 800-457-4584.

#### **COPIES OF THIS PUBLICATION**

If you need additional copies of this publication, please download them from the <u>IHCP Bulletins</u> page of the IHCP provider website at in.gov/medicaid/providers.

### SIGN UP FOR IHCP EMAIL NOTIFICATIONS

To receive email notices of IHCP publications, subscribe by clicking the blue subscription envelope or sign up from the <a href="https://linearchy.org/linea